REIG JOFRE publishes its 2025 first quarter financial results

9 May 2025

REIG JOFRE INCREASED NET PROFIT BY 12% IN A QUARTER MARKED BY OPERATIONAL OPTIMISATION AND INTERNATIONAL FOCUS

  • REIG JOFRE increases its net profit by 12% to €3.7 million in a first quarter marked by operational improvements and progress in equity-accounted projects. Revenue rose by 2% to €88 million, driven by the Consumer Healthcare division.
  • Business outside Spain continued to be key to growth, increasing by 11% and now accounting for 60% of total sales.
  • EBITDA stood at €9.9 million, with a margin of 11.24% on sales, remaining in line with the profitability achieved at the end of 2024.
  • The company remains committed to industrial investment and improving productivity, with an investment of €2.5 million, mainly in the Toledo plant, aimed at increasing manufacturing capacity and reducing unit costs.
  • These results reinforce REIG JOFRE’s goal of universalising the science that matters through an innovative, sustainable and global business model.
  • Events after the reporting period: Participation in the European IPCEI Med4Cure project

REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the Spanish Stock Exchange (BME), closed the first quarter of 2025 with a 2% increase in revenue, reaching €88 million, during a period of transition and operational improvements focused on increasing profitability and consolidating its global expansion. This growth was led by the Consumer Healthcare Division, with an increase of +9%.

EBITDA stood at €9.9 million, with a margin of 11.2% on sales, remaining in line with the end of the 2024 financial year. Consolidated net profit increased by +12% to €3.7 million, supported by operational improvements and the positive impact of joint ventures, such as progress in Syna Therapeutics’ biosimilar and at Leanbio SL.

International expansion and geographic diversification

International expansion remained one of the main drivers for growth at REIG JOFRE. In the quarter, markets outside Spain already accounted for 60% of revenues, with +11% year-on-year growth. This progress reflects the company’s strategic focus on reducing its dependence on the domestic market.